436 related articles for article (PubMed ID: 26908078)
1. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
6. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Lim JS; Soo RA
Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
[TBL] [Abstract][Full Text] [Related]
8. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
9. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M; Schouten RD; De Gooijer CJ; Baas P
Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
[TBL] [Abstract][Full Text] [Related]
12. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Gettinger S; Herbst RS
Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
Gridelli C; de Marinis F; Di Maio M; Ardizzoni A; Belani CP; Cappuzzo F; Ciardiello F; Fidias P; Paz-Ares L; Perrone F; Pirker R; De Petris L; Stahel R
Lung Cancer; 2012 Jun; 76(3):269-79. PubMed ID: 22266040
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab for treating non-small cell lung cancer.
Guibert N; Mazières J
Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
[TBL] [Abstract][Full Text] [Related]
17. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
18. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
19. A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.
Aguiar PN; Santoro IL; Tadokoro H; de Lima Lopes G; Filardi BA; Oliveira P; Castelo-Branco P; Mountzios G; de Mello RA
Immunotherapy; 2016 Sep; 8(9):1011-9. PubMed ID: 27485075
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
